TTY Biopharm Co (ROCO:4105) Short-Term Debt: NT$1,651 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4105 TTY Biopharm Co Ltd ROCO:4105
85 GF Score
Price NT$77.90
GF Value NT$87.60
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is TTY Biopharm Co Short-Term Debt?

TTY Biopharm Co ROCO:4105 -0.38% 85 Short-Term Debt is NT$1,651 Mil as of Jun. 2026. GuruFocus rates ROCO:4105 with a GF Score™ of 85/100 and a GF Value™ of NT$87.60 (Modestly Undervalued). The stock has 1 warning sign investors should review.

TTY Biopharm Co's Short-Term Debt for the quarter that ended in Jun. 2026 was NT$1,651 Mil.

TTY Biopharm Co's quarterly Short-Term Debt declined from Dec. 2025 (NT$1,210 Mil) to Mar. 2026 (NT$1,019 Mil) but then increased from Mar. 2026 (NT$1,019 Mil) to Jun. 2026 (NT$1,651 Mil).

TTY Biopharm Co's annual Short-Term Debt increased from Dec. 2023 (NT$1,506 Mil) to Dec. 2024 (NT$1,650 Mil) but then declined from Dec. 2024 (NT$1,650 Mil) to Dec. 2025 (NT$1,210 Mil).

TTY Biopharm Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

TTY Biopharm Co Short-Term Debt Related Terms

TTY Biopharm Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for TTY Biopharm Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TTY Biopharm Co Short-Term Debt Chart

TTY Biopharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,176.21 1,851.83 1,506.13 1,650.40 1,209.64

TTY Biopharm Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,117.62 1,912.15 1,209.64 1,019.36 1,651.15
ROCO:4105
85GF Score
TTY Biopharm Co Ltd ROCO:4105
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of NT$1,651 Mil mean?
TTY Biopharm Co (ROCO:4105) has a Short-Term Debt of NT$1,651 Mil as of Jun. 2026.
Is TTY Biopharm Co's Short-Term Debt too high?
TTY Biopharm Co's current Short-Term Debt is NT$1,651 Mil. Overall, TTY Biopharm Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Short-Term Debt compare to ZTS?
TTY Biopharm Co's Short-Term Debt of NT$1,651 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. TTY Biopharm Co's current Short-Term Debt is NT$1,651 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.60, compared to a current price of NT$77.90 — trading 11.1% below its estimated fair value. The current Short-Term Debt is NT$1,651 Mil. TTY Biopharm Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Short-Term Debt is NT$1,651 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?

Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued. The current stock price of NT$77.90 is trading 11.1% below its estimated GF Value™ of NT$87.60. GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.

Key valuation signals for ROCO:4105:

  • Short-Term Debt: NT$1,651 Mil
  • GF Value™: NT$87.60 vs. price of NT$77.90 (11.1% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TTY Biopharm Co Business Description

Address No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
85GF Score

Get the complete analysis for ROCO:4105

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.90
Price
NT$87.60
GF Value